Clinical Trials Logo

Alcoholic Hepatitis clinical trials

View clinical trials related to Alcoholic Hepatitis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02442180 Terminated - Alcoholic Hepatitis Clinical Trials

Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid

GraCiAH
Start date: July 2015
Phase: Phase 3
Study type: Interventional

Steroid is the treatment of choice in patients with severe alcoholic hepatitis. However, null- or partial responder of steroid treatment is recommended to consider liver transplantation. The yearly demand for liver transplants far exceeds the supply of available organs and alcoholic liver disease has been a controversial indication for transplantation. Granulocyte-Colony Stimulating Factor (G-CSF) has been reported to have effect of proliferation of hepatic progenitors in alcoholic steatohepatitis. The aim of this study is to investigate the efficacy of G-CSF in patients with severe alcoholic hepatitis with null or partial response to steroid.

NCT ID: NCT02039219 Terminated - Alcoholic Hepatitis Clinical Trials

Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)

TREAT
Start date: November 3, 2014
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to test the effectiveness of Obeticholic Acid when used in patients with moderately severe alcoholic hepatitis. The researchers suspect that individuals with alcoholic hepatitis have certain abnormalities in how their body handles bile acids (a product made by the liver on a daily basis) produced by the liver. Obeticholic acid has been shown to affect bile acid abnormalities and thus it is possible that obeticholic acid may improve liver condition in individuals with alcoholic hepatitis.

NCT ID: NCT01912404 Terminated - Alcoholic Hepatitis Clinical Trials

Study of IDN-6556 in Patients With Severe AH and Contradictions to Steroid Therapy

AH
Start date: July 2013
Phase: Phase 2
Study type: Interventional

The main purpose of the study is to test if taking a study drug called emricasan (also known as IDN-6556 and PF-03491390) will affect overall patient survival after one month of treatment.